TrialDiabetes, obesity & metabolism2022

Improved glycaemic control and weight benefit with iGlarLixi versus insulin glargine 100 U/mL in Chinese people with type 2 diabetes advancing their therapy from basal insulin plus oral antihyperglycaemic drugs: Results from the LixiLan-L-CN randomized controlled trial.

Xiaoyong Yuan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.